RNA interference‐mediated knockdown of α‐synuclein protects human dopaminergic neuroblastoma cells from MPP+ toxicity and reduces dopamine transport
Identifieur interne : 000F72 ( Main/Exploration ); précédent : 000F71; suivant : 000F73RNA interference‐mediated knockdown of α‐synuclein protects human dopaminergic neuroblastoma cells from MPP+ toxicity and reduces dopamine transport
Auteurs : Timothy M. Fountaine [Royaume-Uni] ; Richard Wade-Martins [Royaume-Uni]Source :
- Journal of Neuroscience Research [ 0360-4012 ] ; 2007-02-01.
English descriptors
- KwdEn :
Abstract
The critical observation in the pathology of Parkinson's disease (PD) is that neurodegeneration is largely restricted to dopaminergic neurons that develop cytoplasmic inclusions called Lewy bodies. These aggregations contain the protein α‐synuclein. Furthermore, it is becoming apparent that α‐synuclein expression levels are a major factor in PD pathogenesis. Patients with additional copies of the α‐synuclein gene develop PD with a severity proportional to levels of α‐synuclein overexpression. Similarly, overexpression of α‐synuclein in in vitro and in vivo models has been shown to be toxic. However, little is known about the effects of reducing α‐synuclein expression in human neurons. To investigate this, we have developed a system in which levels of α‐synuclein can be acutely suppressed by using RNA interference (RNAi) in a physiologically relevant human dopaminergic cellular model. By using small interfering RNA (siRNA) molecules targeted to endogenous α‐synuclein, we achieved 80% protein knockdown. We show that α‐synuclein knockdown has no effect on cellular survival either under normal growth conditions over 5 days or in the presence of the mitochondrial inhibitor rotenone. Knockdown does, however, confer resistance to the dopamine transporter (DAT)‐dependent neurotoxin N‐methyl‐4‐phenylpyridinium (MPP+). We then demonstrate for the first time that α‐synuclein suppression decreases dopamine transport in human cells, reducing the maximal uptake velocity (Vmax) of dopamine and the surface density of its transporter by up to 50%. These results show that RNAi‐mediated α‐synuclein knockdown alters cellular dopamine homeostasis in human cells and may suggest a mechanism for the increased survival in the presence of MPP+, a toxin used extensively to model Parkinson's disease. © 2006 Wiley‐Liss, Inc.
Url:
DOI: 10.1002/jnr.21125
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">RNA interference‐mediated knockdown of α‐synuclein protects human dopaminergic neuroblastoma cells from MPP+ toxicity and reduces dopamine transport</title><author><name sortKey="Fountaine, Timothy M" sort="Fountaine, Timothy M" uniqKey="Fountaine T" first="Timothy M." last="Fountaine">Timothy M. Fountaine</name></author><author><name sortKey="Wade Artins, Richard" sort="Wade Artins, Richard" uniqKey="Wade Artins R" first="Richard" last="Wade-Martins">Richard Wade-Martins</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:23B43DAE5A3BCDC8F3AD735046C24E491BFA5507</idno><date when="2007" year="2007">2007</date><idno type="doi">10.1002/jnr.21125</idno><idno type="url">https://api.istex.fr/document/23B43DAE5A3BCDC8F3AD735046C24E491BFA5507/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">002C81</idno><idno type="wicri:Area/Main/Curation">002908</idno><idno type="wicri:Area/Main/Exploration">000F72</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">RNA interference‐mediated knockdown of α‐synuclein protects human dopaminergic neuroblastoma cells from MPP+ toxicity and reduces dopamine transport</title><author><name sortKey="Fountaine, Timothy M" sort="Fountaine, Timothy M" uniqKey="Fountaine T" first="Timothy M." last="Fountaine">Timothy M. Fountaine</name><affiliation wicri:level="4"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>The Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford</wicri:regionArea><placeName><settlement type="city">Oxford</settlement><region type="country">Angleterre</region><region type="comté" nuts="2">Oxfordshire</region></placeName><orgName type="university">Université d'Oxford</orgName></affiliation></author><author><name sortKey="Wade Artins, Richard" sort="Wade Artins, Richard" uniqKey="Wade Artins R" first="Richard" last="Wade-Martins">Richard Wade-Martins</name><affiliation wicri:level="4"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>The Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford</wicri:regionArea><placeName><settlement type="city">Oxford</settlement><region type="country">Angleterre</region><region type="comté" nuts="2">Oxfordshire</region></placeName><orgName type="university">Université d'Oxford</orgName></affiliation></author></analytic><monogr></monogr><series><title level="j">Journal of Neuroscience Research</title><title level="j" type="abbrev">J. Neurosci. Res.</title><idno type="ISSN">0360-4012</idno><idno type="eISSN">1097-4547</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2007-02-01">2007-02-01</date><biblScope unit="volume">85</biblScope><biblScope unit="issue">2</biblScope><biblScope unit="page" from="351">351</biblScope><biblScope unit="page" to="363">363</biblScope></imprint><idno type="ISSN">0360-4012</idno></series><idno type="istex">23B43DAE5A3BCDC8F3AD735046C24E491BFA5507</idno><idno type="DOI">10.1002/jnr.21125</idno><idno type="ArticleID">JNR21125</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0360-4012</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>DAT</term><term>MPTP</term><term>Parkinson's disease</term><term>neurodegeneration</term><term>rotenone</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The critical observation in the pathology of Parkinson's disease (PD) is that neurodegeneration is largely restricted to dopaminergic neurons that develop cytoplasmic inclusions called Lewy bodies. These aggregations contain the protein α‐synuclein. Furthermore, it is becoming apparent that α‐synuclein expression levels are a major factor in PD pathogenesis. Patients with additional copies of the α‐synuclein gene develop PD with a severity proportional to levels of α‐synuclein overexpression. Similarly, overexpression of α‐synuclein in in vitro and in vivo models has been shown to be toxic. However, little is known about the effects of reducing α‐synuclein expression in human neurons. To investigate this, we have developed a system in which levels of α‐synuclein can be acutely suppressed by using RNA interference (RNAi) in a physiologically relevant human dopaminergic cellular model. By using small interfering RNA (siRNA) molecules targeted to endogenous α‐synuclein, we achieved 80% protein knockdown. We show that α‐synuclein knockdown has no effect on cellular survival either under normal growth conditions over 5 days or in the presence of the mitochondrial inhibitor rotenone. Knockdown does, however, confer resistance to the dopamine transporter (DAT)‐dependent neurotoxin N‐methyl‐4‐phenylpyridinium (MPP+). We then demonstrate for the first time that α‐synuclein suppression decreases dopamine transport in human cells, reducing the maximal uptake velocity (Vmax) of dopamine and the surface density of its transporter by up to 50%. These results show that RNAi‐mediated α‐synuclein knockdown alters cellular dopamine homeostasis in human cells and may suggest a mechanism for the increased survival in the presence of MPP+, a toxin used extensively to model Parkinson's disease. © 2006 Wiley‐Liss, Inc.</div></front></TEI><affiliations><list><country><li>Royaume-Uni</li></country><region><li>Angleterre</li><li>Oxfordshire</li></region><settlement><li>Oxford</li></settlement><orgName><li>Université d'Oxford</li></orgName></list><tree><country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Fountaine, Timothy M" sort="Fountaine, Timothy M" uniqKey="Fountaine T" first="Timothy M." last="Fountaine">Timothy M. Fountaine</name></region><name sortKey="Wade Artins, Richard" sort="Wade Artins, Richard" uniqKey="Wade Artins R" first="Richard" last="Wade-Martins">Richard Wade-Martins</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000F72 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000F72 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:23B43DAE5A3BCDC8F3AD735046C24E491BFA5507
|texte= RNA interference‐mediated knockdown of α‐synuclein protects human dopaminergic neuroblastoma cells from MPP+ toxicity and reduces dopamine transport
}}
| This area was generated with Dilib version V0.6.23. |  |